Home

NEWS:

2nd Annual International NUT Carcinomia Symposium in Nov 2026
Sign up for our mailing list to receive information about the upcoming meeting here.

Study Paves Path to Improved Diagnosis, Treatment of NUT Carcinoma
NUT carcinoma is defined by fusions of the NUTM1 gene with other genes. Gene fusions occur when errors in the genome glue two genes together, resulting in the production of a malfunctioning protein.

Jia Luo, MD and co-senior author Christopher French, MD, of Brigham and Women’s Hospital, initiated the study to determine the best means of detecting these gene fusions and definitively diagnosing NUT carcinoma. They examined the diagnostic results of 116 NUT carcinoma tumors that had undergone molecular testing using a range of panel tests including next-generation DNA sequencing, circulating tumor DNA (ctDNA) testing, and tests that identify gene fusions.

They found that DNA sequencing and ctDNA testing detected NUT fusions less than 25 percent of the time. In contrast, NUT IHC, RNA fusion testing, and NUTM1 FISH testing detected NUT carcinoma fusions much more reliably, respectively 100 percent, 84 percent, and 92 percent of the time. “These findings warrant immediate change to the diagnostic workflow for patients with suspected NUT carcinoma,” says Luo.  The findings were published in Clinical Cancer Research.

FDA Grants Fast Track Status to ZEN-3694 Plus Abemaciclib for Unresectable or Metastatic NUT Carcinoma

The FDA has granted fast track designation to ZEN-3694 for use in combination with abemaciclib (Verzenio) for the treatment of patients with unresectable or metastatic NUT carcinoma who have received at least 1 prior line of chemotherapy.

The agent is currently under evaluation in a phase 1 trial (NCT05372640) in combination with abemaciclib in adult and pediatric patients with unresectable or metastatic NUT carcinoma, breast cancer, and other solid tumors.

Read here for full article.